The FDA has approved AstraZeneca's Imfinzi with gemcitabine and cisplatin as neoadjuvant treatment in adults with MIBC.

With a plan to unveil the non-invasive prostate treatment on the horizon and a push for more robotic surgery training, ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...

Learn the 7 vital bladder cancer warning signs that require immediate medical attention, including subtle early symptoms many ...

AstraZenecas drug Imfinzi (NASDAQ: AZN) has received U.S. approval to treat adult patients with muscle-invasive bladder ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Leveraging the power of AI and machine learning technologies, researchers at Weill Cornell Medicine developed a more ...

AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...

In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...

AstraZeneca's treatment for adults with muscle-invasive bladder cancer was approved in the U.S.

However, other types of bladder cancer, such as adenocarcinoma, squamous cell carcinoma, and small cell carcinoma, spread much faster. In most cases, treatment started early enough can prevent the ...

The promotional effort from Ferring features bladder cancer survivors sharing the news of a new treatment option.